Igate Clinical Research International is categorized under Medical Labs in Pittsburgh, PA and active since 2005.
Igate Clinical Research International was established in 2005, and today employs 1 to 4, earning Unknown per year. This is a Medical Labs business, which does work in the B2C market, and is classified as a Medical Labs, under code number 5419100 by the NAICS.
If you are seeking more information, feel free to contact Micheal Zugay at the company’s single location by writing to 2000 Cliffmine Road # 410, Pittsburgh, Pennsylvania PA 15275 or by phoning (412) 490-9620. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Igate Clinical Research International |
Contact Person: | Micheal Zugay |
Address: | 2000 Cliffmine Road # 410, Pittsburgh, Pennsylvania 15275 |
Phone Number: | (412) 490-9620 |
Website Address: | igate.com |
Annual Revenue (USD): | Unknown |
Founded: | 2005 |
Location Type: | Single Location |
Employee Number: | 1 to 4 |
Business Type: | B2C (Business to Consumer) |
Business Category: | Medical Labs |
SIC Code: | 8071 |
NAICS Code: | 5419100 |
Share This Business: |
Igate Clinical Research International was started in 2005 to provide professional Medical Labs under the SIC code 8071 and NAICS code 5419100. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact Micheal Zugay for inquiries that concern Igate Clinical Research International by calling the company number (412) 490-9620, as your correspondence is most welcome. Additionally, the physical location of the single location of Igate Clinical Research International can be found at the coordinates 40.45755,-80.19243 as well as the street address 2000 Cliffmine Road # 410 in Pittsburgh, Pennsylvania 15275.
For its online presence, you may visit Igate Clinical Research International’s website at igate.com and engage with its social media outlets through on Twitter and on Facebook.